An AI breakthrough could lead to a silver bullet for Alzheimer’s and offer a faster, cheaper way to find life-changing drugs.
Though gene therapies can be expensive on their own, they should only need to be administered once.
Even after five years on the market, the promised benefits aren't showing up.
The use of nitroprusside and isoproterenol dropped by 53 percent and 35 percent over three years, as their prices skyrocketed by factors of ten.
A new report finds it takes an average of 10 months for the federal regulatory agency to sign off on sales of new pharmaceuticals.
Millions in the U.S. don’t know they are suffering from a deadly liver disease; Big Pharma is eager to cash in.
A new analysis suggests government funding for studies is shrinking, forcing researchers to turn to the pharmaceutical industry to support essential research.
Preliminary results from a phase 2 trial found the maintenance therapy may be even more effective at achieving viral suppression than three daily antiretroviral pills.
The investigation involves Retrophin, a public company where Shkreli served as an officer, director, and 10-percent owner.
A fractured regulatory system hampered by Big Pharma’s meddling has led to a growing global falsification market.
The settlement is the largest ever reached by the Federal Trade Commission.
With a price tag of $1,000 a day, most patients are unable to get treatment.